Lasater, E. A., Amin, D. N., Bannerji, R., Mali, R. S., Barrett, K., Rys, R. N., Oeh, J., Lin, E., Sterne‐Weiler, T., Ingalla, E. R., Go, M., Yu, S., Krem, M. M., Arthur, C., Hahn, U., Johnston, A., Karur, V., Khan, N., Marlton, P., Phillips, T., Gritti, G., Seymour, J. F., Tani, M., Yuen, S., Martin, S., Chang, M. T., Rose, C. M., Pham, V. C., Polson, A. G., Chang, Y., Wever, C., Johnson, N. A., Jiang, Y., Hirata, J., Sampath, D., Musick, L., Flowers, C. R., & Wertz, I. E. (2023). targeting MCL‐1 and BCL‐2 with polatuzumab vedotin and venetoclax overcomes treatment resistance in R/R non‐Hodgkin lymphoma: Results from preclinical models and a Phase Ib study. American journal of hematology, 98(3), 449–463. http://access.bl.uk/ark:/81055/vdc_100177578359.0x00004b